结核分枝杆菌耐丙硫异烟胺相关基因研究进展  

Progress on Drug Resistance Related Genes of Mycobacterium Tuberculosis to Protionamide

作　　者：谭旎 张泓[1] TAN Ni;ZHANG Hong(The Second Department of Respiratory Medicine,the Affiliated hospital of Zunyi Medical College,Zunyi 563003,China)

机构地区：[1]遵义医学院附属医院呼吸二科,贵州省遵义市563003

出　　处：《实用心脑肺血管病杂志》2018年第11期11-15,共5页Practical Journal of Cardiac Cerebral Pneumal and Vascular Disease

基　　金：国家自然科学基金资助项目(81760003)

摘　　要：据世界卫生组织(WHO)统计,2017年全球范围内新发利福平耐药结核病患者数量约为55.8万,其中约82%为耐多药结核病(MDR-TB),而约8.5%的MDR-TB患者为广泛耐药结核病(XDR-TB),MDR-TB、XDR-TB的出现使全球结核病防控工作面临着巨大挑战。丙硫异烟胺(Pto)为二线抗结核药物之一,近年来其耐药机制研究尤其是耐药基因研究取得一定进展。本文综述了结核分枝杆菌耐Pto相关基因,旨在为结核分枝杆菌对Pto的耐药机制研究提供参考。According to the statistics of WHO,the amount of newly diagnosed patients with rifampicin-resistant tuberculosis(RR-TB)was about 558,000 all of the world in 2017,of which about 82% were MDR-TB,and the proportion of extensively drug-resistant tuberculosis was about 8.5% in patients with MDR-TB. Occurrence of MDR-TB and XDR-TB brings enormous challenge to the global tuberculosis prevention and control efforts. Prothionamide is one of second-line anti-tuberculosis drug,and some progress on its resistance mechanism especially on drug resistance related genes has been made in recent years. This paper reviewed the drug resistance related genes of Mycobacterium tuberculosis to protionamide,in order to provide a reference for the research on resistance mechanism to prothionamide.

关 键 词：结核分枝杆菌 结核 抗多种药物性 广泛耐药结核 丙硫异烟胺 基因 突变 综述 

分 类 号：R378.911[医药卫生—病原生物学] R394.2[医药卫生—基础医学]